|
| 36597662 | Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. | Cancer | 2023 |
| 37579145 | Triple-negative breast tumors are dependent on mutant p53 for growth and survival. | Proc Natl Acad Sci U S A | 2023 |
| 37565350 | Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. | J Pathol | 2023 |
| 37782315 | Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. | Clin Cancer Res | 2023 |
| 37768670 | Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 36900183 | Dominant Gene Expression Profiles Define Adenoid Cystic Carcinoma (ACC) from Different Tissues: Validation of a Gene Signature Classifier for Poor Survival in Salivary Gland ACC. | Cancers (Basel) | 2023 |
| 36898078 | Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. | J Clin Oncol | 2023 |
| 37449360 | Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. | Clin Cancer Res | 2023 |
| 37256648 | Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. | Clin Cancer Res | 2023 |
| 36549347 | Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37114470 | Targeting human EGFR 2 (HER2) in salivary gland carcinoma. | Expert Rev Anticancer Ther | 2023 |
| 36597662 | Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. | Cancer | 2023 |
| 37782315 | Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. | Clin Cancer Res | 2023 |
| 37579145 | Triple-negative breast tumors are dependent on mutant p53 for growth and survival. | Proc Natl Acad Sci U S A | 2023 |
| 37768670 | Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37565350 | Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. | J Pathol | 2023 |
| 37256648 | Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. | Clin Cancer Res | 2023 |
| 37449360 | Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. | Clin Cancer Res | 2023 |
| 37114470 | Targeting human EGFR 2 (HER2) in salivary gland carcinoma. | Expert Rev Anticancer Ther | 2023 |
| 36549347 | Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 36900183 | Dominant Gene Expression Profiles Define Adenoid Cystic Carcinoma (ACC) from Different Tissues: Validation of a Gene Signature Classifier for Poor Survival in Salivary Gland ACC. | Cancers (Basel) | 2023 |
| 36898078 | Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. | J Clin Oncol | 2023 |
| 34661906 | Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. | Cancer | 2022 |
| 35954356 | Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. | Cancers (Basel) | 2022 |
| 35419587 | Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. | Clin Cancer Res | 2022 |
| 35932620 | Primary and recurrent regional metastases for lateralized oral cavity squamous cell carcinoma. | Surg Oncol | 2022 |
| 36124629 | Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. | Oncologist | 2022 |
| 35320355 | Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. | Cancer Res | 2022 |
| 34661906 | Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. | Cancer | 2022 |
| 35419587 | Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. | Clin Cancer Res | 2022 |
| 35932620 | Primary and recurrent regional metastases for lateralized oral cavity squamous cell carcinoma. | Surg Oncol | 2022 |
| 35954356 | Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. | Cancers (Basel) | 2022 |
| 36124629 | Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. | Oncologist | 2022 |
| 35320355 | Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. | Cancer Res | 2022 |
| 32680839 | Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. | Br J Ophthalmol | 2021 |
| 33806894 | Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. | Cancers (Basel) | 2021 |
| 34285950 | Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. | Int J Part Ther | 2021 |
| 34285940 | Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. | Int J Part Ther | 2021 |
| 34011559 | Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations. | Clin Cancer Res | 2021 |
| 33522021 | Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. | Head Neck | 2021 |
| 33990543 | LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. | Oncogenesis | 2021 |
| 33603199 | Retraction Note to: The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. | Br J Cancer | 2021 |
| 34187851 | Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. | Clin Cancer Res | 2021 |
| 34358340 | Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. | Cancer | 2021 |
| 33320343 | Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. | Cancer | 2021 |
| 33352413 | Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. | Eur J Cancer | 2021 |
| 32680839 | Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. | Br J Ophthalmol | 2021 |
| 33172898 | Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. | Clin Cancer Res | 2021 |
| 32946597 | Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. | Laryngoscope | 2021 |
| 33417831 | Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. | Cancer Cell | 2021 |